The abstract is read at the publisher; the summary is JClub's.
Early adjunctive middle meningeal artery embolisation with Onyx in symptomatic chronic subdural haematoma reduced the 90-day composite of recurrence-related outcomes from 49.0% to 32.7%.
- Why it matters: Recurrence after standard management remains a problem, and prior randomised evidence for MMA embolisation has been inconsistent. This trial tests whether adding early embolisation improves outcomes after surgery.
- What they did: In six French hospitals, adults were randomised 1:1 to standard treatment plus early MMA embolisation (within 5 days of surgery) or standard treatment alone, with masked outcome assessment. The modified intention-to-treat analysis used patients with an assessable primary outcome.
- The result: The composite primary outcome occurred in 36/110 versus 51/104, with an absolute risk difference of -16·31 percentage points (95% CI -29·32 to -3·30; nominal p=0·015), and reoperation was 7.3% versus 18.3%. Mortality at 90 days was 4.5% versus 3.8%, and procedure-related serious adverse events were 9.1% versus 8.7%, with no embolisation-related deaths or ischaemic strokes.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.